JRS
Major Contributor
That's a very well done study, and I am frankly surprised that it was approved by the University IRB (board that has to sign off on human experimentation, lots of Fed regs). I am really glad for the link: in essence it is looking at whether Ketamine more closely resembles schizophrenia than other drugs. For a while psychedelics (LSD, mushrooms, etc) were seen as a window into psychosis, but it fails on multiple accounts. A much better model is amphetamines which reliably induces profound paranoia with extended use. We would see this in the ER all the time--basically very difficult without toxicology or patient report to know whether it was an acute episode of schizophrenia or meth madness. Either way the antipsychotics bring about improvement in a matter of a few days. It dovetails nicely into the excess dopamine model of psychosis/schizophrenia because that it was it does: causes massive amts of dopamine to be released, and the cure just so happens to block dopamine receptors, Tidy story, right?Maybe this was the study the City Paper was referring to: Effects of Ketamine in Normal and Schizophrenic Volunteers .
Not exactly, and so that's why there has been such keen interest in the role of excitatory receptors (NMDA) as the fundamental insult to the nervous system of schizophrenics. There may be some gold to be mined; they recently approved an NMDA blocker for the treatment of psychosis associated with Parkinson's. This is the first agent of it's type that doesn't effect dopamine levels but still helps to control psychosis. Again thanks for the link. I still am shaking my head--that took stones to give ketamine to schizophrenics!
Last edited: